Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Double signal activates killer cells

No. 58c | 14/11/2014 | by Koh

Scientists from the German Cancer Research Center (DKFZ) have found out that natural killer cells need at least two separate signals in order to be able to fight cytomegaloviruses. This finding might help to find more effective treatments against this virus, which is particularly dangerous for leukemia patients in the wake of bone marrow transplants.


In healthy people, infections with human cytomegalovirus (HCMV) normally do not cause any symptoms. By contrast, in persons with a weakened immune system such as leukemia patients in the wake of a bone marrow transplantation, the virus can lead to life-threatening complications. HCMV is also life-threatening for unborn babies. No other pathogenic agent is transferred so frequently during pregnancy from the mother to the fetus.

A well functioning immune defense of the body normally keeps the viruses in check, primarily using its “innate arm”* with its prime “weapons” called natural killer cells (NK cells). A small portion of these killer cells has an activating receptor molecule called CD94/NKG2C on their surface. It is exactly this group of NK cells that multiplies strongly during an HCMV infection. So far, the molecular signals underlying this process had remained in the dark; now they have been deciphered.

In order to determine the factors that are required for the specific NK cell proliferation during an HCMV infection, researchers in the department of Dr. Adelheid Cerwenka at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) cultivated HCMV infected connective tissue cells along with immune cells from the blood of healthy donors.

They found out that specific immune cells – monocytes that carry the surface marker CD14 – are indispensable for the proliferation of NK cells carrying CD94/NKG2C because they produce a chemical messenger called IL-12. When the researchers neutralized IL-12, the NK cell proliferation was strongly reduced. However, not only the chemical messenger is necessary but also the actual presence of the CD14 monocytes.

Cerwenka’s team additionally discovered that NK cells carrying CD94/NKG2C proliferate only if the infected cells exhibit the HLA-E molecule on their surface. HLA-E is the binding partner of the receptor CD94/NKG2C. It is closely related to the presentation molecules that are indispensable for antigens in adaptive immunity. HCMV infected cells increase the production of HLA-E.

“The activation of the NK cells by the cytomegalovirus is a complex process that involves many different molecules. We have now been able to identify a signal 1 (mediated by HLA-E) and a signal 2 (mediated by IL-12 and monocytes) that are both necessary for the proliferation of NK cells that exhibit the activating CD94/NKG2C receptor,” says Alexander Rölle, one of the two first authors of the publication.

“This activation strongly resembles the double signal that is required to make the adaptive immune system ready to attack,” says Adelheid Cerwenka, an immunologist at the DKFZ, who headed the study. She continues: ”Following an activating contact with an antigen (signal 1), the T and B cells of the adaptive immune system need the presence of so-called co-stimulating signals (signal 2) in order to multiply and thus mount a defense. The exact knowledge of these interactions may help us to treat patients with life-threatening HCMV infections more effectively by supporting the activation of their NK cells. Since NK cells also play an important role in tumor defense, this finding might also advance the development of cancer immunotherapies.”

Alexander Rölle, Julia Pollmann, Eva-Maria Ewen, Anne Halenius, Hartmut Hengel and Adelheid Cerwenka: IL-12-producing monocytes and HLA-E control HCMV-driven NKG2C+ NK cell expansion. Journal of Cinical Investigation 2014, DOI: 10.1172/JCI77440

*The body’s defense system is made up of the innate and the adaptive immune systems. The innate system is responsible for immediate defense of the body. Cells of the innate system do not have specific receptors but respond to a broad spectrum of pathogens (using phagocytes, granulocytes) or transformed body cells (using NK cells). By contrast, T and B lymphocytes, which are part of the adaptive immune system, are equipped with highly specific receptor molecules directed against protein components of specific pathogens. If these long-lived cells, which form a sort of memory of the immune system, encounter this specific invader again, they first have to multiply before they can mount an effective defense. Therefore, several days pass before the adaptive immune defense is ready to fight the attack.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS